Aptevo Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $-220 | $0 |
Gross Profit | -35 | -81 | ||
EBITDA | -6,530 | -6,662 | -5,725 | -7,500 |
EBIT | -6,697 | -5,806 | -7,549 | |
Net Income | -6,356 | -6,697 | -5,806 | -7,549 |
Net Change In Cash | 0 | 0 | -220 | 0 |
Free Cash Flow | -5,454 | -7,965 | -5,236 | -6,688 |
Cash | 9,797 | 14,525 | 21,619 | 21,061 |
Basic Shares | 1,196 | 1,060 | 997 | 224 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $3,114 |
Gross Profit | -240 | -352 | -567 | 3,114 |
EBITDA | -25,727 | -23,778 | -18,083 | 7,915 |
EBIT | -25,967 | -24,130 | -18,650 | 7,014 |
Net Income | -25,967 | -24,130 | -17,411 | 8,027 |
Net Change In Cash | 0 | 0 | 0 | 3,114 |
Free Cash Flow | -25,592 | -23,785 | -11,730 | -21,051 |
Cash | 21,619 | 8,714 | 16,904 | 22,635 |
Basic Shares | 3 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$5.31 |
2026-03-31 | -$6.41 |
2025-12-31 | -$5.91 |
2025-09-30 | -$40.14 |